The interview reflects on the incremental evolution of the pancreatic cancer treatment paradigm, with chemotherapy remaining the backbone while molecular profiling gradually identifies small patient subgroups for targeted approaches. It discusses how treatment decisions vary by disease stage, the cautious adoption of maintenance and targeted therapies, and the potential of novel agents and modalities, such as RAS inhibition, immunomodulation, and device-based interventions, to broaden future options.

This interview was conducted on 22 July 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.